# US 2010/0166749 A1 · Polypeptide variants with altered effector function

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0166749 A1
- Document ID: US20100166749A1
- Status: Published application
- Kind: A1
- Application number: 12/590,801
- Filed: 2009-11-12
- Published: 2010-07-01
- Earliest claimed: 1999-01-15
- Assignees: Genentech, Inc.
- Inventors: Leonard Presta
- Web page: https://patentgrep.com/patent/US20100166749A1

## CPC

- C07K 16/4291: {against IgE}
- A61P 11/06: Antiasthmatics
- A61P 35/00: Antineoplastic agents
- A61P 37/02: Immunomodulators
- C07K 16/00: Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K 16/22: against growth factors {; against growth regulators}
- C07K 16/2887: {against CD20}
- G01N 33/6857: {Antibody fragments}
- C07K 2317/55: Fab or Fab'
- C07K 2317/71: Decreased effector function due to an Fc-modification
- C07K 2317/72: Increased effector function due to an Fc-modification
- C07K 2317/732: Antibody-dependent cellular cytotoxicity [ADCC]
- C07K 2317/734: Complement-dependent cytotoxicity [CDC]
- C07K 2319/00: Fusion polypeptide
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention concerns polypeptides comprising a variant Fc region. More particularly, the present invention concerns Fc region-containing polypeptides that have altered effector function as a consequence of one or more amino acid modifications in the Fc region thereof.

## Claims

### Claim 1

A variant of a parent polypeptide comprising an Fc region, which variant mediates antibody-dependent cell-mediated cytotoxicity (ADCC) in the presence of human effector cells more effectively, or binds an Fc gamma receptor (FcγR) with better affinity, than the parent polypeptide and comprises at least one amino acid modification in the Fc region.

### Claim 2 (depends on 1)

The variant of claim 1 which comprises an antibody.

### Claim 3 (depends on 1)

The variant of claim 1 wherein the parent polypeptide Fc region comprises a human IgG Fc region.

### Claim 4 (depends on 3)

The variant of claim 3 wherein the human IgG Fc region comprises a human IgG1, IgG2, IgG3 or IgG4 Fc region.

### Claim 5 (depends on 1)

The variant of claim 1 which mediates ADCC about 1.5 fold to about 100 fold more effectively than the parent polypeptide.

### Claim 6 (depends on 1)

The variant of claim 1 which binds an FcγRIII with better affinity than the parent polypeptide.

### Claim 7 (depends on 6)

The variant of claim 6 which further binds an FcγRII with worse affinity than the parent polypeptide.

### Claim 8 (depends on 1)

The variant of claim 1 which comprises at least one amino acid substitution in the Fc region.

### Claim 9 (depends on 1)

The variant of claim 1 which comprises at least one amino acid modification in a CH2 domain of the Fc region.

### Claim 10 (depends on 1)

The variant of claim 1 which comprises at least one amino acid modification in the Fc region, other than in a lower hinge region thereof.

### Claim 11 (depends on 1)

The variant of claim 1 which comprises an amino acid substitution at any one or more of amino acid positions 256, 290, 298, 312, 326, 330, 333, 334, 360, 378 or 430 of the Fc region, wherein the numbering of the residues in the Fc region is that of the EU index as in Kabat.

### Claim 12 (depends on 11)

The variant of claim 11 which comprises two or more amino acid substitutions at the amino acid positions listed therein.

### Claim 13 (depends on 11)

The variant of claim 11 which comprises three or more amino acid substitutions at the amino acid positions listed therein.

### Claim 14

A polypeptide comprising a variant Fc region with altered Fc gamma receptor (FcγR) binding affinity, which polypeptide comprises an amino acid modification at any one or more of amino acid positions 238, 239, 248, 249, 252, 254, 255, 256, 258, 265, 267, 268, 269, 270, 272, 276, 278, 280, 283, 285, 286, 289, 290, 292, 293, 294, 295, 296, 298, 301, 303, 305, 307, 309, 312, 315, 320, 322, 324, 326, 327, 329, 330, 331, 333, 334, 335, 337, 338, 340, 360, 373, 376, 378, 382, 388, 389, 398, 414, 416, 419, 430, 434, 435, 437, 438 or 439 of the Fc region, wherein the numbering of the residues in the Fc region is that of the EU index as in Kabat.

### Claim 15 (depends on 14)

The polypeptide of claim 14 wherein the variant Fc region comprises a variant human IgG Fc region.

### Claim 16 (depends on 14)

The polypeptide of claim 14 which displays reduced binding to an FcγR and comprises an amino acid modification at any one or more of amino acid positions 238, 239, 248, 249, 252, 254, 265, 268, 269, 270, 272, 278, 289, 292, 293, 294, 295, 296, 298, 301, 303, 322, 324, 327, 329, 333, 335, 338, 340, 373, 376, 382, 388, 389, 414, 416, 419, 434, 435, 437, 438 or 439 of the Fc region, wherein the numbering of the residues in the Fc region is that of the EU index as in Kabat.

### Claim 17 (depends on 14)

The polypeptide of claim 14 which displays reduced binding to an FcγRI.

### Claim 18 (depends on 17)

The polypeptide of claim 17 which displays reduced binding to the FcγRI and comprises an amino acid modification at any one or more of amino acid 238, 265, 269, 270, 327 or 329 of the Fc region, wherein the numbering of the residues in the Fc region is that of the EU index as in Kabat.

### Claim 19 (depends on 14)

The polypeptide of claim 14 which displays reduced binding to an FcγRII.

### Claim 20 (depends on 19)

The polypeptide of claim 19 which displays reduced binding to the FcγRII and comprises an amino acid modification at any one or more of amino acid positions 238, 265, 269, 270, 292, 294, 295, 298, 303, 324, 327, 329, 333, 335, 338, 373, 376, 414, 416, 419, 435, 438 or 439 of the Fc region, wherein the numbering of the residues in the Fc region is that of the EU index as in Kabat.

### Claim 21 (depends on 14)

The polypeptide of claim 14 which displays reduced binding to an FcγRIII.

### Claim 22 (depends on 21)

The polypeptide of claim 21 which displays reduced binding to the FcγRIII and comprises an amino acid modification at any one or more of amino acid 238, 239, 248, 249, 252, 254, 265, 268, 269, 270, 272, 278, 289, 293, 294, 295, 296, 301, 303, 322, 327, 329, 338, 340, 373, 376, 382, 388, 389, 416, 434, 435 or 437 of the Fc region, wherein the numbering of the residues in the Fc region is that of the EU index as in Kabat.

### Claim 23 (depends on 14)

The polypeptide of claim 14 which displays increased binding to an FcγR and comprises an amino acid modification at any one or more of amino acid positions 255, 256, 258, 267, 268, 272, 276, 280, 283, 285, 286, 290, 298, 301, 305, 307, 309, 312, 315, 320, 322, 326, 330, 331, 333, 334, 337, 340, 360, 378, 398 or 430 of the Fc region, wherein the numbering of the residues in the Fc region is that of the EU index as in Kabat.

### Claim 24 (depends on 23)

The polypeptide of claim 23 which displays increased binding to an FcγRIII.

### Claim 25 (depends on 24)

The polypeptide of claim 24 which further displays decreased binding to an FcγRII.

### Claim 26 (depends on 25)

The polypeptide of claim 25 which displays increased binding to the FcγRIII and further displays decreased binding to the FcγRII, wherein the polypeptide comprises an amino acid modification at positions 298 and/or 333 of the Fc region, wherein the numbering of the residues in the Fc region is that of the EU index as in Kabat.

### Claim 27 (depends on 23)

The polypeptide of claim 23 which displays increased binding to an FcγRII.

### Claim 28 (depends on 27)

The polypeptide of claim 27 which displays increased binding to the FcγRII and comprises an amino acid modification at any one or more of amino acid 255, 256, 258, 267, 268, 272, 276, 280, 283, 285, 286, 290, 301, 305, 307, 309, 312, 315, 320, 322, 326, 330, 331, 337, 340, 378, 398 or 430 of the Fc region, wherein the numbering of the residues in the Fc region is that of the EU index as in Kabat.

### Claim 29 (depends on 27)

The polypeptide of claim 27 which further displays decreased binding to an FcγRIII.

### Claim 30 (depends on 29)

The polypeptide of claim 29 which displays increased binding to the FcγRII and further displays decreased binding to the FcγRIII, wherein the polypeptide comprises an amino acid modification at any one or more of amino acid positions 268, 272, 298, 301, 322 or 340 of the Fc region, wherein the numbering of the residues in the Fc region is that of the EU index as in Kabat.

### Claim 31

A polypeptide comprising a variant Fc region with altered neonatal Fc receptor (FcRn) binding affinity, which polypeptide comprises an amino acid modification at any one or more of amino acid positions 238, 252, 253, 254, 255, 256, 265, 272, 286, 288, 303, 305, 307, 309, 311, 312, 317, 340, 356, 360, 362, 376, 378, 380, 382, 386, 388, 400, 413, 415, 424, 433, 434, 435, 436, 439 or 447 of the Fc region, wherein the numbering of the residues in the Fc region is that of the EU index as in Kabat.

### Claim 32 (depends on 31)

The polypeptide of claim 31 which displays reduced binding to an FcRn.

### Claim 33 (depends on 32)

The polypeptide of claim 32 which displays reduced binding to the FcRn and comprises an amino acid modification at any one or more of amino acid positions 252, 253, 254, 255, 288, 309, 386, 388, 400, 415, 433, 435, 436, 439 or 447 of the Fc region, wherein the numbering of the residues in the Fc region is that of the EU index as in Kabat.

### Claim 34 (depends on 31)

The polypeptide of claim 31 which displays increased binding to FcRn.

### Claim 35 (depends on 34)

The polypeptide of claim 34 which displays increased binding to FcRn and comprises an amino acid modification at any one or more of amino acid positions 238, 256, 265, 272, 286, 303, 305, 307, 311, 312, 317, 340, 356, 360, 362, 376, 378, 380, 382, 413, 424 or 434 of the Fc region, wherein the numbering of the residues in the Fc region is that of the EU index as in Kabat.

### Claim 36 (depends on 14)

The polypeptide of claim 14 which displays reduced binding to FcγRI, FcγRIIA, FcγRIIB and FcγRIIIA and comprises an amino acid modification at any one or more of amino acid positions 238, 265, 327 or 329 of the Fc region, wherein the numbering of the residues in the Fc region is that of the EU index as in Kabat.

### Claim 37 (depends on 14)

The polypeptide of claim 14 which displays reduced binding to FcγRII and FcγRIIIA and comprises an amino acid modification at any one or more of amino acid positions 270, 295 or 327 of the Fc region, wherein the numbering of the residues in the Fc region is that of the EU index as in Kabat.

### Claim 38 (depends on 14)

The polypeptide of claim 14 which displays increased binding to FcγRII and FcγRIIIA and comprises an amino acid modification at any one or more of amino acid positions 256 or 290 of the Fc region, wherein the numbering of the residues in the Fc region is that of the EU index as in Kabat.

### Claim 39 (depends on 14)

The polypeptide of claim 14 which displays increased binding to FcγRII but unchanged binding to FcγRIIIA and comprises an amino acid modification at any one or more of amino acid positions 255, 258, 267, 272, 276, 280, 285, 286, 307, 309, 315, 326, 331, 337, 378 or 430 of the Fc region, wherein the numbering of the residues in the Fc region is that of the EU index as in Kabat.

### Claim 40 (depends on 14)

The polypeptide of claim 14 which displays increased binding to FcγRII and reduced binding to FcγRIIIA and comprises an amino acid modification at any one or more of amino acid positions 268, 301 or 322 of the Fc region, wherein the numbering of the residues in the Fc region is that of the EU index as in Kabat.

### Claim 41 (depends on 14)

The polypeptide of claim 14 which displays reduced binding to FcγRII but unchanged FcγRIIIA binding and comprises an amino acid modification at any one or more of amino acid positions 292 or 414 of the Fc region, wherein the numbering of the residues in the Fc region is that of the EU index as in Kabat.

### Claim 42 (depends on 14)

The polypeptide of claim 14 which displays reduced binding to FcγRII and improved binding to FcγRIIIA and comprises an amino acid modification at amino acid position 298 of the Fc region, wherein the numbering of the residues in the Fc region is that of the EU index as in Kabat.

### Claim 43 (depends on 14)

The polypeptide of claim 14 which displays reduced binding to FcγRIIIA but unchanged FcRII binding and comprises an amino acid modification at any one or more of amino acid positions 239, 269, 293, 296, 303, 327, 338 or 376 of the Fc region, wherein the numbering of the residues in the Fc region is that of the EU index as in Kabat.

### Claim 44 (depends on 14)

The polypeptide of claim 14 which displays improved binding to FcγRIIIA but unchanged FcRII binding and comprises an amino acid modification at any one or more of amino acid positions 333 or 334 of the Fc region, wherein the numbering of the residues in the Fc region is that of the EU index as in Kabat.

### Claim 45 (depends on 31)

The polypeptide of claim 31 which displays altered binding to FcRn but unchanged FcγR binding and comprises an amino acid modification at any one or more of amino acid positions 253, 254, 288, 305, 311, 312, 317, 360, 362, 380, 382, 415, 424, 433, 434, 435 or 436 of the Fc region, wherein the numbering of the residues in the Fc region is that of the EU index as in Kabat.

### Claim 46 (depends on 1)

The polypeptide of claim 1 which comprises an amino acid modification at any one or more of amino acid positions 298, 333 or 334 of the Fc region, wherein the numbering of the residues in the Fc region is that of the EU index as in Kabat.

### Claim 47 (depends on 1)

The polypeptide of claim 1 which comprises amino acid modifications at two or more of amino acid positions 298, 333, 334 or 339 of the Fc region, wherein the numbering of the residues in the Fc region is that of the EU index as in Kabat.

### Claim 48 (depends on 46)

The polypeptide of claim 46 which comprises an amino acid modification at amino acid position 298 of the Fc region, wherein the numbering of the residues in the Fc region is that of the EU index as in Kabat.

### Claim 49 (depends on 46)

The polypeptide of claim 46 which comprises amino acid modifications at amino acid positions 298 and 334 of the Fc region, wherein the numbering of the residues in the Fc region is that of the EU index as in Kabat.

### Claim 50 (depends on 46)

The polypeptide of claim 46 which comprises amino acid modifications at three or more of amino acid positions 298, 333, 334 or 339 of the Fc region, wherein the numbering of the residues in the Fc region is that of the EU index as in Kabat.

### Claim 51 (depends on 46)

The polypeptide of claim 46 which comprises amino acid modifications at amino acid positions 298, 333 and 334 of the Fc region, wherein the numbering of the residues in the Fc region is that of the EU index as in Kabat.

### Claim 52 (depends on 1)

The polypeptide of claim 1 which further displays increased binding to neonatal Fc receptor (FcRn).

### Claim 53 (depends on 33)

The polypeptide of claim 33 which comprises an amino acid modification at one or more of amino acid positions 253, 254, 435 or 436 of the Fc region, wherein the numbering of the residues in the Fc region is that of the EU index as in Kabat.

### Claim 54 (depends on 35)

The polypeptide of claim 35 which comprises an amino acid modification at one or more of amino acid positions 238, 256, 307, 311, 312, 380, 382 or 434 of the Fc region, wherein the numbering of the residues in the Fc region is that of the EU index as in Kabat.

### Claim 55 (depends on 54)

The polypeptide of claim 54 which comprises amino acid modifications at two or all of amino acid positions 307, 380 and 434 of the Fc region, wherein the numbering of the residues in the Fc region is that of the EU index as in Kabat.

### Claim 56 (depends on 55)

The polypeptide of claim 55 which comprises amino acid modifications at amino acid positions 307, 380 and 434 of the Fc region, wherein the numbering of the residues in the Fc region is that of the EU index as in Kabat.

### Claim 57

A polypeptide comprising a variant Fc region which comprises amino acid modifications at amino acid positions 298, 333 and 334 of the Fc region, wherein the numbering of the residues in the Fc region is that of the EU index as in Kabat.

### Claim 58

A polypeptide comprising a variant Fc region which comprises amino acid modifications at amino acid positions 298 and 334 of the Fc region, wherein the numbering of the residues in the Fc region is that of the EU index as in Kabat.

### Claim 59

A polypeptide comprising a variant Fc region which comprises an amino acid modification at amino acid position 298 of the Fc region, wherein the numbering of the residues in the Fc region is that of the EU index as in Kabat.

### Claim 60

A polypeptide comprising a variant Fc region with altered affinity for an FcγR allotype, which polypeptide comprises an amino acid modification at any one or more of amino acid positions 265, 267, 268, 270, 290, 298, 305, 307, 315, 317, 320, 331, 333 or 334 of the Fc region, wherein the numbering of the residues in the Fc region is that of the EU index as in Kabat.

### Claim 61 (depends on 60)

The polypeptide of claim 60 wherein the FcγRIII allotype is selected from the group consisting of FcγRIIIA-Phe158, FcγRIIIA-Val158, FcγRIIA-R131 and FcγRIIA-H131.

### Claim 62 (depends on 60)

The polypeptide of claim 60 which displays increased binding to FcγRIIIA-Phe158.

### Claim 63 (depends on 62)

The polypeptide of claim 62 comprising an amino acid modification at any one or more of amino acid positions 290, 298, 333 or 334 of the Fc region, wherein the numbering of the residues in the Fc region is that of the EU index as in Kabat.

### Claim 64

A polypeptide comprising a variant Fc region which comprises amino acid modifications at two or all of amino acid positions 307, 380 and 434 of the Fc region, wherein the numbering of the residues is that of the EU index as in Kabat.

### Claim 65 (depends on 64)

The polypeptide of claim 64 which comprises amino acid modifications at amino acid positions 307, 380 and 434 of the Fc region, wherein the numbering of the residues is that of the EU index as in Kabat.

### Claim 66 (depends on 1)

A composition comprising the polypeptide variant of claim 1 and a pharmaceutically acceptable carrier.

### Claim 67 (depends on 66)

The composition of claim 66 which is sterile.

### Claim 68 (depends on 1)

Isolated nucleic acid encoding the polypeptide variant of claim 1.

### Claim 69 (depends on 68)

A vector comprising the nucleic acid of claim 68.

### Claim 70 (depends on 69)

A host cell containing the vector of claim 69.

### Claim 71 (depends on 70)

A method for producing a polypeptide variant comprising culturing the host cell of claim 70 so that the nucleic acid is expressed.

### Claim 72 (depends on 71)

The process of claim 71 further comprising recovering the polypeptide variant from the host cell culture.

### Claim 73 (depends on 1)

A method for treating a disorder in a mammal comprising administering to the mammal a therapeutically effective amount of the polypeptide variant of claim 1.

### Claim 74

A method for making a variant Fc region with altered Fc receptor (FcR) binding affinity, or altered antibody-dependent cell-mediated cytotoxicity (ADCC) activity, comprising:
(a) introducing one or more amino acid modifications into an Fc region of a parent polypeptide in order to generate a variant Fc region;
(b) determining binding of the variant Fc region to an FcR, or determining ADCC activity of the variant Fc region.

### Claim 75 (depends on 74)

The method of claim 74 wherein step (b) comprises determining binding of the variant Fc region to an FcR in vitro.

### Claim 76 (depends on 74)

The method of claim 74 wherein step (b) comprises identifying a variant Fc region with improved FcR binding affinity, or with improved ADCC activity.

### Claim 77 (depends on 74)

The method of claim 74 wherein the FcR is human Fc gamma receptor III (FcγRIII).

### Claim 78 (depends on 74)

The method of claim 74 wherein step (b) comprises determining binding of the variant Fc region to at least two different FcRs.

### Claim 79 (depends on 79)

The method of claim 79 wherein the Fc receptors include human Fc gamma receptor II (FcγRII) and human Fc gamma receptor III (FcγRIII).
